secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0000950170-24-073116
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia shareholders approve officer liability limitation, re-elect directors at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment limiting officer liability under DGCL; 69M for, 2.9M against.
- Fred Cohen and Frank Verwiel re-elected as Class II directors with 65.4M and 55.8M votes for, respectively.
- Deloitte & Touche ratified as auditor for FY2024; 83.5M for, 256.7K against.
- Say-on-pay proposal passed with 70.4M for, 1.5M against.
- Certificate of Second Amendment filed with Delaware Secretary of State on June 12, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024073116/0000950170-24-073116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024073116/ntla-20240612.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer